The first patients in Soliton’s cellulite trial have been treated, the Company reports.

"Patient treatments have now begun at the Chicago site,” says Dr. Chris Capelli, President, CEO and co-founder of Soliton, in a news release.  "It is incredibly exciting to have arrived at this point of the study.  A tremendous amount of work goes into preparing for a study of this magnitude and treating the first patients is quite rewarding."

The Soliton Rapid Acoustic Pulse ("RAP") device applies rapid pulses of acoustic shockwaves to the surface of the patients' skin to create mechanical stress at the cellular level and induces significant collagen growth in a single 20-minute, non-invasive treatment. The treatments required no anesthesia, caused no bruising, swelling or infection, and were evaluated by the trial participants as a "0" on a pain scale of 0-10 in 97 percent of the treatments during a proof of concept trial.  None of the patients experienced any post-treatment downtime.  

The Soliton device is investigational and is not available for sale in the United States. The Company's first FDA cleared commercial product will use rapid pulses of acoustic shockwaves as an accessory to lasers for the removal of unwanted tattoos.